TCGA-56-8309-01A-11R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.510
- APICAL_SURFACE+0.490
- IL6_JAK_STAT3_SIGNALING+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- INFLAMMATORY_RESPONSE+0.380
- COMPLEMENT+0.350
- WNT_BETA_CATENIN_SIGNALING+0.340
- TNFA_SIGNALING_VIA_NFKB+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- OXIDATIVE_PHOSPHORYLATION-0.530
- MYC_TARGETS_V1-0.520
- E2F_TARGETS-0.380
- DNA_REPAIR-0.300
- G2M_CHECKPOINT-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.240
- MTORC1_SIGNALING-0.220
- FATTY_ACID_METABOLISM-0.210
- PROTEIN_SECRETION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.921 |
| 2 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.919 |
| 3 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.917 |
| 4 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.916 |
| 5 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.910 |
| 6 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.905 |
| 7 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.904 |
| 8 | C3N-02923 | — | cohortMD2 | 0.897 |
| 9 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.896 |
| 10 | SRR8613789 | — | A | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.490 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |